Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma

NCT04443829 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT04443829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04443829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma
Lead sponsor
University College, London
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 23, 2021
Completion date
December 31, 2032
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary cns lymphoma